BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/12/2026 6:40:16 AM | Browse: 13 | Download: 13
 |
Received |
|
2026-02-24 07:32 |
|
Peer-Review Started |
|
2026-02-24 07:32 |
|
First Decision by Editorial Office Director |
|
2026-03-02 08:48 |
|
Return for Revision |
|
2026-03-02 08:48 |
|
Revised |
|
2026-03-13 01:32 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-04-08 02:40 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-04-08 03:51 |
|
Articles in Press |
|
2026-04-08 03:51 |
|
Edit the Manuscript by Language Editor |
|
2026-04-14 20:11 |
|
Typeset the Manuscript |
|
2026-04-30 06:49 |
|
Publish the Manuscript Online |
|
2026-05-12 06:40 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Case Report |
| Article Title |
Dramatic response to fourth-line ramucirumab after atezolizumab plus bevacizumab failure in advanced hepatocellular carcinoma: A case report
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Masanori Fukushima, Yasuhiko Nakao, Ryu Sasaki, Masafumi Haraguchi, Satoshi Miuma and Hisamitsu Miyaaki |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Masanori Fukushima, Department of Gastroenterology and Hepatology,, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1, Nagasaki 8528501, Japan. ma-fukushima@nagasaki-u.ac.jp |
| Key Words |
Alpha-fetoprotein; Atezolizumab plus bevacizumab; Child-Pugh B; Hepatocellular carcinoma; Later-line therapy; Ramucirumab; Tyrosine kinase inhibitor intolerance; Case report |
| Core Tip |
Hepatocellular carcinoma with elevated alpha-fetoprotein levels that progresses following atezolizumab plus bevacizumab administration may involve enhanced vascular endothelial growth factor receptor-2 signaling, making ramucirumab a potentially effective treatment option. |
| Publish Date |
2026-05-12 06:40 |
| Citation |
Fukushima M, Nakao Y, Sasaki R, Haraguchi M, Miuma S, Miyaaki H. Dramatic response to fourth-line ramucirumab after atezolizumab plus bevacizumab failure in advanced hepatocellular carcinoma: A case report. World J Clin Cases 2026; 14(15): 119781 |
| URL |
https://www.wjgnet.com/2307-8960/full/v14/i15/119781.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v14.i15.119781 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
